West Australian researchers are racing to create a new treatment to prevent and protect people from the potentially life-threatening complications of type 2 diabetes after being awarded new funding to fast-track their quest.
Associate Professor Kevin Pfleger and his Perth-based team will receive $60,000 to progress their work into a molecule called RAGE (the Receptor for Advanced Glycation End-products).
A/Professor Pfleger explained to us that RAGE was a molecule that sat in the membrane surrounding cells that were injured or stressed.
“As RAGE is only present when cells are in this injured or stressed mode – which happens in type 2 diabetes – it’s a key target that we believe we can hone in on to possibly prevent and definitely use to help fight the health effects of this condition,” he explained.
“With our collaborators, we’ve discovered a new way in which this molecule is activated, triggering a cascade of signalling in cells that leads to inflammation and cell injury, and we’ve found a way to inhibit this process which should, in turn, limit the complications of type 2 developing, so it’s incredibly exciting.”
Our executive director Sherl Westlund congratulated A/Professor Pfleger.
“This project could be a significant game-changer in the treatment of type 2 diabetes as there remains an unmet need for innovative treatment strategies to manage this condition, and shows how Western Australia is at the forefront of advances in this field,” she said.
The work will also harness powerful bioluminescence resonance energy transfer (BRET) technology, developed at the University of Western Australia, that A/Professor Pfleger is well-known for using in his cutting-edge research.
The project is being done in collaboration with leading diabetes researcher Professor Merlin Thomas from Australia’s Monash University.